The Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine, Nanchang, 330006, Jiangxi Province, China.
Jiangxi University of Traditional Chinese Medicine, Nanchang, 330004, Jiangxi Province, China.
Biomed Pharmacother. 2021 May;137:111299. doi: 10.1016/j.biopha.2021.111299. Epub 2021 Jan 25.
Natural killer group 2, member D (NKG2D) receptor is a crucial activating receptor in the immune recognition and eradication of abnormal cells by natural killer (NK) cells, and T lymphocytes. NKG2D can transmit activation signals and activate the immune system by recognizing the NKG2D ligands (NKG2D-L) on acute myeloid leukemia (AML) cells. Downregulation of NKG2D-L in AML can circumvent resistance to chemotherapy and immune recognition. Considering this effect, the exploration of targeting the NKG2D/NKG2D-L axis is considered to have tremendous potential for the discovery of novel biomacromolecule antibodies and pharmacological modulators in AML. This review was to outline the impact of NKG2D/NKG2D-L axis on intrinsic immunosurveillance and the development of AML. Furthermore, the NKG2D/NKG2D-L axis related modulators and progress in preclinical and clinical trials was also to be reviewed.
自然杀伤细胞群 2 成员 D（NKG2D）受体是自然杀伤（NK）细胞和 T 淋巴细胞识别和清除异常细胞的关键激活受体。NKG2D 通过识别急性髓系白血病（AML）细胞上的 NKG2D 配体（NKG2D-L），可以传递激活信号并激活免疫系统。AML 中 NKG2D-L 的下调可以规避化疗和免疫识别的耐药性。考虑到这种作用，靶向 NKG2D/NKG2D-L 轴的探索被认为在 AML 中发现新型生物大分子抗体和药理学调节剂方面具有巨大潜力。本综述旨在概述 NKG2D/NKG2D-L 轴对固有免疫监视和 AML 发展的影响。此外，还对 NKG2D/NKG2D-L 轴相关调节剂以及临床前和临床试验的进展进行了综述。
